Logo image of CPTA

Capitala Finance Crp (CPTA) Stock Fundamental Analysis

NASDAQ:CPTA - Nasdaq -

25.4  +0.85 (+3.46%)

Fundamental Rating

2

Overall CPTA gets a fundamental rating of 2 out of 10. We evaluated CPTA against 232 industry peers in the Capital Markets industry. CPTA has a bad profitability rating. Also its financial health evaluation is rather negative. CPTA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CPTA has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA 6.05%
ROE 15.95%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -2.29%
PM (TTM) 79.62%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

CPTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of 0.08, we must say that CPTA is in the distress zone and has some risk of bankruptcy.
CPTA has a Debt/Equity ratio of 1.60. This is a high value indicating a heavy dependency on external financing.
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF N/A
Altman-Z 0.08
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 14.72 indicates that CPTA has no problem at all paying its short term obligations.
CPTA has a Quick Ratio of 14.72. This indicates that CPTA is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 14.72
Quick Ratio 14.72

More info and screens

2

3. Growth

3.1 Past

CPTA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -103.33%.
The earnings per share for CPTA have been decreasing by -57.96% on average. This is quite bad
Looking at the last year, CPTA shows a very negative growth in Revenue. The Revenue has decreased by -36.77% in the last year.
The Revenue for CPTA have been decreasing by -16.20% on average. This is quite bad
EPS 1Y (TTM)-103.33%
EPS 3Y-73.39%
EPS 5Y-57.96%
EPS Q2Q%125.7%
Revenue 1Y (TTM)-36.77%
Revenue growth 3Y-19.71%
Revenue growth 5Y-16.2%
Sales Q2Q%-30.36%

3.2 Future

Based on estimates for the next years, CPTA will show a very strong growth in Earnings Per Share. The EPS will grow by 64.41% on average per year.
Based on estimates for the next years, CPTA will show a very negative growth in Revenue. The Revenue will decrease by -22.03% on average per year.
EPS Next Y170.69%
EPS Next 2Y138.5%
EPS Next 3Y94.04%
EPS Next 5Y64.41%
Revenue Next Year-34.4%
Revenue Next 2Y-22.29%
Revenue Next 3Y-22.31%
Revenue Next 5Y-22.03%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CPTA Yearly Revenue VS EstimatesCPTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CPTA Yearly EPS VS EstimatesCPTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8 10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CPTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 34.35, which means the current valuation is very expensive for CPTA.
When comparing the Price/Forward Earnings ratio of CPTA to the average of the S&P500 Index (22.30), we can say CPTA is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 34.35
CPTA Price Earnings VS Forward Price EarningsCPTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150 -200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -4.73
CPTA Per share dataCPTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPTA's earnings are expected to grow with 94.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y138.5%
EPS Next 3Y94.04%

More info and screens

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.88%, CPTA is a good candidate for dividend investing.
CPTA's Dividend Yield is rather good when compared to the S&P500 average which is at 2.38.
Industry RankSector Rank
Dividend Yield 5.88%

5.2 History

The dividend of CPTA decreases each year by -32.37%.
CPTA has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-32.37%
Div Incr YearsN/A
Div Non Decr YearsN/A
CPTA Yearly Dividends per shareCPTA Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2 4 6 8 10

5.3 Sustainability

DPN/A
EPS Next 2Y138.5%
EPS Next 3Y94.04%

More info and screens

Capitala Finance Crp

NASDAQ:CPTA (7/1/2021, 8:00:00 PM)

25.4

+0.85 (+3.46%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.06%
Inst Owner Change0%
Ins Owners17.04%
Ins Owner Change0%
Market Cap68.86M
Analysts60
Price Target15.3 (-39.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.88%
Yearly Dividend1.49
Dividend Growth(5Y)-32.37%
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 34.35
P/S 2.83
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB N/A
EV/EBITDA -4.73
EPS(TTM)-0.11
EYN/A
EPS(NY)0.74
Fwd EY2.91%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.96
BVpS44.74
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 6.05%
ROE 15.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -2.29%
PM (TTM) 79.62%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 1.6
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.72
Quick Ratio 14.72
Altman-Z 0.08
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-103.33%
EPS 3Y-73.39%
EPS 5Y-57.96%
EPS Q2Q%125.7%
EPS Next Y170.69%
EPS Next 2Y138.5%
EPS Next 3Y94.04%
EPS Next 5Y64.41%
Revenue 1Y (TTM)-36.77%
Revenue growth 3Y-19.71%
Revenue growth 5Y-16.2%
Sales Q2Q%-30.36%
Revenue Next Year-34.4%
Revenue Next 2Y-22.29%
Revenue Next 3Y-22.31%
Revenue Next 5Y-22.03%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A